CHARLES M BALCH to Lymphocytes, Tumor-Infiltrating
This is a "connection" page, showing publications CHARLES M BALCH has written about Lymphocytes, Tumor-Infiltrating.
Connection Strength
0.151
-
Genetic and immune characteristics of sentinel lymph node metastases and multiple lymph node metastases compared to their matched primary breast tumours. EBioMedicine. 2021 Sep; 71:103542.
Score: 0.035
-
Characterization of autologous tumor-specific T-helper 2 cells in tumor-infiltrating lymphocytes from a patient with metastatic melanoma. Int J Cancer. 1994 Aug 01; 58(3):317-23.
Score: 0.021
-
Immunological properties of melanoma tumor-infiltrating lymphocytes before and after IL-2-based biotherapies. In Vivo. 1991 Nov-Dec; 5(6):647-53.
Score: 0.018
-
Study of tumor-infiltrating lymphocytes for adoptive therapy of renal cell carcinoma (RCC) and metastatic melanoma: sequential proliferation of cytotoxic natural killer and noncytotoxic T cells in RCC. J Immunother (1991). 1991 Oct; 10(5):313-25.
Score: 0.018
-
Alteration in interactions between tumor-infiltrating lymphocytes and tumor cells in human melanomas after chemotherapy or immunotherapy. Cancer Immunol Immunother. 1991; 33(4):238-46.
Score: 0.017
-
In vitro migration of lymphocytes through collagen matrix: arrested locomotion in tumor-infiltrating lymphocytes. Cancer Res. 1990 Nov 15; 50(22):7153-8.
Score: 0.017
-
2010 TNM staging system for cutaneous melanoma...and beyond. Ann Surg Oncol. 2010 Jun; 17(6):1475-7.
Score: 0.016
-
Impairment of lymphocyte locomotion in the tumor microenvironment and the effect of systemic immunotherapy with liposome-encapsulated muramyl-tripeptide-phosphatidylethanolamine. Cancer Immunol Immunother. 1995 Jan; 40(1):57-64.
Score: 0.006
-
Cytokine production and immune cell activation in melanoma patients treated with liposomal muramyl tripeptide (CGP 19835A lipid). Cancer Biother. 1993; 8(4):307-18.
Score: 0.005